
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp reported third quarter 2025 revenue of $21.5 million, marking a 5% increase year-over-year, driven by the adoption of its Zephyr Valve for severe emphysema. The company maintained an impressive gross margin of 75% while narrowing its net loss to $14.0 million, reflecting improved operational efficiency. Furthermore, with international sales increasing by 15%, Pulmonx's focus on disciplined execution, along with promising initiatives surrounding AeriSeal and AI-driven tools, underlines the company’s potential for sustainable growth.
Bears say
Pulmonx Corp's Q3 revenue of approximately $21.5 million reflects a sequential decline from Q2's $23.9 million, indicating a slower growth trajectory and contributing to a downward revision of annual revenue guidance to $90 million–$92 million. Additionally, the company's top-line growth and gross margins, which were at 72% in Q2, have been negatively impacted by mix and conversion timing issues. The recent management transition, with Glen French returning as CEO and Derrick Sung appointed as COO/CFO, introduces additional execution risks that may further weigh on the company's financial performance.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares